BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

August 26, 2026 | News

Pulnovo Medical Enrols First Patients in PULSE-LHD Trial for Pulmonary Hypertension

Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), announced the enrollment of the f...

August 24, 2026 | News

South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal

HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including ob...

August 25, 2026 | News

CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416

CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...

August 24, 2026 | News

US FDA Grants Breakthrough Therapy and Fast Track Designations to NORROY’s 68Ga-NYM096 for Kidney Cancer Imaging

NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food ...

August 21, 2026 | News

Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Partner on Large-Scale Lung Cancer Genomic Screening in Japan

Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medience") announced a collaboration to support genomic screeni...

August 21, 2026 | News

Ingenia Therapeutics Debuts on KOSDAQ to Accelerate Next-Gen Vascular Antibody Pipeline

Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that its shares have begun t...

August 21, 2026 | News

Connext Completes Phase 2 Enrollment of CNT201 for Dupuytren’s Contracture

All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive d...

August 19, 2026 | News

Optellum, Coreline Soft Join Forces to Build Integrated AI Pathway for Lung Nodule Care

Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform &nbs...

August 17, 2026 | News

China Accepts Laekna’s NDA for Afuresertib in Advanced Breast Cancer

Laekna (2105.HK) announced that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China'...

August 13, 2026 | News

Thermo Fisher, Michael J. Fox Foundation Expand Parkinson’s Proteomics Resource with 5,500 Samples

Olink™ Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher...

August 13, 2026 | News

Top-Rated Functional Medicine Doctors in Denver for Comprehensive Care

The challenge is real: separating genuinely trained practitioners from people marketing wellness without the science to back it up is harder than it should...

August 11, 2026 | News

Neurocrine Initiates Phase I Trial of Triple Agonist NBIP-’1968 for Obesity

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pi...

August 10, 2026 | News

Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic

Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...

August 07, 2026 | News

Stay Connected